Complement C3a receptor-mediated vascular dysfunction: a complex interplay between aging and neurodegeneration.
Journal
The Journal of clinical investigation
ISSN: 1558-8238
Titre abrégé: J Clin Invest
Pays: United States
ID NLM: 7802877
Informations de publication
Date de publication:
04 01 2021
04 01 2021
Historique:
entrez:
4
1
2021
pubmed:
5
1
2021
medline:
26
8
2021
Statut:
ppublish
Résumé
Vascular dysfunction resulting in compromised blood-brain barrier (BBB) integrity is evident in aging and disease. Although the complement C3a/C3a receptor (C3a/C3aR) axis influences normal brain aging and disease progression, the mechanisms governing endothelial C3aR-mediated neurovascular inflammation and BBB permeability remain unexplored. In this issue of the JCI, Propson et al. investigated endothelial C3a/C3aR signaling in normal, aged, and neurodegenerative mouse models. Endothelial C3aR signaling modulated age-dependent increases in VCAM1, initiated peripheral lymphocyte infiltration, and enhanced microglial activity. Increased calcium release downstream of C3aR signaling disrupted the vascular endothelial cadherin (VE-cadherin) junctions, increased BBB permeability, and degraded vascular structure and function. Mice lacking C3aR (C3ar1-/-) and mice treated with a C3aR antagonist showed attenuated age-related microglial reactivity and neurodegeneration. These results confirm that complement-mediated signaling impacts vascular health and BBB function in normal aging and neurodegenerative disease, suggesting that complement inhibitors represent a therapeutic option for cerebral microvascular dysfunction.
Identifiants
pubmed: 33393493
pii: 144348
doi: 10.1172/JCI144348
pmc: PMC7773380
doi:
pii:
Substances chimiques
Receptors, Complement
0
complement C3a receptor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Comment
Langues
eng
Sous-ensembles de citation
IM
Commentaires et corrections
Type : CommentOn
Références
Neuroepidemiology. 2019;52(1-2):76-77
pubmed: 30602150
Neuron. 2018 Dec 19;100(6):1337-1353.e5
pubmed: 30415998
Front Neurosci. 2017 Apr 21;11:224
pubmed: 28484368
Neuromolecular Med. 2019 Dec;21(4):467-473
pubmed: 31102134
Science. 2016 Aug 19;353(6301):777-83
pubmed: 27540165
Theranostics. 2020 Jan 1;10(1):74-90
pubmed: 31903107
Cell Rep. 2020 Mar 31;30(13):4418-4432.e4
pubmed: 32234477
Front Physiol. 2012 May 28;3:132
pubmed: 22783194
Cell Res. 2010 Jan;20(1):34-50
pubmed: 20010915
Mol Immunol. 2011 Aug;48(14):1592-603
pubmed: 21546088
J Clin Invest. 2021 Jan 4;131(1):
pubmed: 32990682
Front Immunol. 2018 Jan 25;8:1905
pubmed: 29422891
Mediators Inflamm. 2018 Nov 11;2018:2530414
pubmed: 30533998